Oct 14, 2025
Lisa C. McClain- Amount
- $1,001 to $15,000
- Filed
- Nov 21, 2025
Congress ticker disclosure profile
As of July 20 at 8:00 PM EDT
Public STOCK Act rows mentioning
A factual page for public Congressional disclosures that reference TM. Veridion shows filed rows, disclosed amount ranges, dates, and source links. It does not imply motive or wrongdoing.
90d rows
0
Feed lifetime
19
Member filers
10
Disclosed ranges
$417K
Most active member desks
11 sells vs 8 buys
Republican · House · MI-9
Democrat · House · TN-9
Republican · House · AR-4
Democrat · House · NY-10
Republican · House · MT-0
Republican · House · FL-5
Republican · Senate · OK
Republican · Senate · LA
Public filer · House · TX-15
Republican · House · NJ-3
Latest trade Mar 30, 2026
Oct 14, 2025
Lisa C. McClainAug 13, 2025
Lisa C. McClainJun 24, 2025
Lisa C. McClainApr 21, 2025
Bruce WestermanJul 10, 2023
Daniel S. GoldmanMar 16, 2022
John H. RutherfordMar 26, 2020
Steve CohenMar 18, 2020
Greg Gianforte| Date | Member | Action | Amount | Filed | Receipt |
|---|---|---|---|---|---|
| Oct 14, 2025 | Lisa C. McClain | Sell | $1,001 to $15,000 | Nov 21, 2025 | Open card |
| Aug 13, 2025 | Lisa C. McClain | Buy | $1,001 to $15,000 | Sep 12, 2025 | Open card |
| Jun 24, 2025 | Lisa C. McClain | Sell | $1,001 to $15,000 | Aug 13, 2025 | Open card |
| Apr 21, 2025 | Bruce Westerman | Sell | $1,001 to $15,000 | May 12, 2025 | Open card |
| Jul 10, 2023 | Daniel S. Goldman | Sell | $100,001 to $250,000 | Aug 13, 2023 | Open card |
| Mar 16, 2022 | John H. Rutherford | Sell | $1,001 to $15,000 | Apr 19, 2022 | Open card |
| Mar 26, 2020 | Steve Cohen | Sell | $1,001 to $15,000 | Apr 22, 2020 | Open card |
| Mar 18, 2020 | Greg Gianforte | Buy | $15,001 to $50,000 | Apr 7, 2020 | Open card |
Source creed
This page is assembled from public STOCK Act disclosure records in the Veridion warehouse. 19 of 19 filed rows include disclosed amount ranges (100%). Rows without ranges stay labeled. Identification only; it does not imply motive or wrongdoing.
Disclosure findings, methodology notes, and product updates when we have them. No fixed schedule yet. No advertising list resale.